Dose Dependent Effects on Cell Cycle Checkpoints and DNA Repair by Bendamustine

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin’s lymphoma6

(2011) Michinori Ogura et al.   CANCER SCIENCE

Thymine DNA Glycosylase Is Essential for Active DNA Demethylation by Linked Deamination-Base Excision Repair

(2011) Salvatore Cortellino et al.   CELL

Mechanism of Action: The Unique Pattern of Bendamustine-Induced Cytotoxicity

(2011) Lorenzo M. Leoni et al.   SEMINARS IN HEMATOLOGY

Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma

(2010) Joel S. Owen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

(2010) Michinori Ogura et al.   CANCER SCIENCE

Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation

(2010) Joshua B Stevens et al.   Molecular Cytogenetics

Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling

(2008) G. Roue et al.   CLINICAL CANCER RESEARCH

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

(2008) L. M. Leoni et al.   CLINICAL CANCER RESEARCH

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS